Semaglutide NAION lawsuits in 2026 are based on the failure to warn about this serious eye side effect. These court cases seek legal compensation for patients diagnosed with NAION vision loss or blindness.

In more detail, lawsuits for Wegovy, Rybelsus, and Ozempic vision loss cases involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy (NAION) are filed against Novo Nordisk, the pharmaceutical company responsible for those three semaglutide-containing GLP-1 drugs. This is because, at present, there is no warning about semaglutide-associated NAION in the current drug labels for Ozempic, Rybelsus, and Wegovy.

Some new important evidence for these semaglutide NAION lawsuits involving Ozempic, Rybelsus, and Wegovy is found in this medical journal article published in May 2026 by PLOS Medicine, “Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies“.

From the Abstract for this recent PLOS Medicine medical journal article relevant to Wegovy, Rybelsus, and Ozempic NAION vision loss cases:

Conclusions: Our findings suggest a possible association between semaglutide use and an increased risk of NAION in patients with [type 2 diabetes (T2DM)]. Although the absolute risk is low, clinicians should be aware of this potential adverse event, particularly in individuals at increased baseline risk for optic neuropathies. While these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low, underscoring the need for further high-quality studies to clarify this association.

However, as we pointed out above, the current drug labels for Ozempic, Wegovy, and Rybelsus do not have any warning about semaglutide-associated NAION vision loss or blindness as a possible side effect.

As seen by this list of earlier Drug Injury Law articles, our law firm is very familiar with the semaglutide-associated NAION side effects of Ozempic, Wegovy, and Rybelsus:

• Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
• Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
• Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
• Ozempic Vision Loss Claims Compensation Payments Made in 2025
• Ozempic NAION Rate Higher in Recent 2025 Medical Study
• Link Between Ozempic and NAION Also Involves the Eye Disorder AION
• Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
• Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
• Ozempic Eye Problems Caused by Semaglutide-Related NAION
• Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
• Ozempic Side Effects Include Eye Problems With Possible Vision Loss

In addition, our law firm has experience handling semaglutide NAION lawsuits involving Wegovy, Rybelsus, and Ozempic vision loss or blindness cases for patients.

Patients diagnosed with NAION-related vision loss or blindness can submit an Ozempic/Wegovy/Rybelsus Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about semaglutide NAION lawsuits.

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

A recent Ozempic and Wegovy NAION study made two new findings about people who used Ozempic or Wegovy and then were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) as a drug side effect that caused vision loss. The first is that the Wegovy NAION rate is five times that of Ozempic. The second is that for users of Ozempic and Wegovy, NAION was diagnosed in men three times more than in women.

These findings from the Ozempic and Wegovy NAION study were presented in this March 2026 British Journal of Ophthalmology article, “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk“.

News Articles About

Ozempic and Wegovy NAION Study

Here are three news articles that provide the details and some contextual information about the Ozempic and Wegovy NAION study 2026 report:

“Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs“, MedPage Today, 3/10/26

“Wegovy linked to higher risk of eye stroke and vision loss“, BMJ Group, 3/10/26

“Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds“, The Guardian, 3/10/26

We have been following the vision side-effect drug safety issue that is the subject of this Ozempic and Wegovy NAION study report since July 2024. During that time, we have investigated possible drug injury lawsuits against Novo Nordisk for patients diagnosed with NAION and who suffered vision loss.

Earlier Posts Related to

Ozempic and Wegovy NAION Study

Related to this Ozempic and Wegovy NAION study 2026 report, here is a list of some of our earlier posts about non-arteritic anterior ischemic optic neuropathy (NAION) associated with the semaglutide-containing drugs Wegovy and Ozempic, as well as Rybelsus, all from Novo Nordisk:

• Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
• Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
• Ozempic Vision Loss Claims Compensation Payments Made in 2025
• Ozempic NAION Rate Higher in Recent 2025 Medical Study
• Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
• Link Between Ozempic and NAION Also Involves the Eye Disorder AION
• Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
• Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
• Ozempic Eye Problems Caused by Semaglutide-Related NAION
• Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
• Ozempic Side Effects Include Eye Problems With Possible Vision Loss

If you have a possible NAION drug injury lawsuit involving one of the semaglutide drugs from Novo Nordisk that you want reviewed, you can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

We have written about the Ozempic-NAION side effect drug safety issue several times over the past year-and-a-half, and have repeatedly pointed out that NAION is linked to semaglutide, the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy injection, Wegovy tablet, and Rybelsus tablet. Further, we have suggested that all these Novo Nordisk semaglutide medicines should have NAION warnings, such that there would be Ozempic-NAION warnings, Wegovy-NAION warnings, and Wegovy-NAION warnings.

But as of late January 2026, when the “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” was released, none of the drug labels for Novo Nordisk semaglutide medicines included any NAION warnings.

Before providing some information about why we suggest Ozempic-NAION warnings should be in the recently released January 2026 drug label for the new tablet or pill version of Ozempic that will be available in the US later this year, we direct you to this February 4, 2026, Novo Nordisk USA announcement, “Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026” for some information about that new drug product.

Ozempic-NAION Warnings Information

Here are two earlier articles from our Drug Injury Watch blog that provide support for this suggestion that there should be Ozempic-NAION warnings included in that January 2026 drug label for the new pill version of Ozempic, soon to be available, as well as the current drug label for the already available, and popular, Ozempic injection:

1. “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs”  (2/13/2026)
2. “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness”  (10/22/2025)

The failure by Novo Nordisk to have Ozempic-NAION warnings available for doctors who prescribe Ozempic — or Rybelsus, or Wegovy — as well as the people who use these popular Novo Nordisk semaglutide medicines is the basis for drug injury lawsuits that have been filed against this pharmaceutical company on behalf of people diagnosed with non-arteritic anterior ischemic optic neuropathy, or NAION.

If you have been diagnosed with NAION while using one of those Novo Nordisk semaglutide medicines or soon thereafter, you may want to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.

In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic NAION drug injury lawsuit that you want evaluated by drug injury attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Some compensation payments for Ozempic vision loss claims are being made in Europe, according to recent news reports.

From this November 21, 2025, article, “Denmark Compensates Four Over Vision Loss Linked To Ozempic, Wegovy“, published by the Agence France Presse (AFP):

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.

More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.

The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.

The association said that it had ruled on five cases so far, and found four people who merited compensation….

In Denmark, health authorities generally pay out medical compensation for a drug injury such as NAION linked to Ozempic.  The Danish Patient Compensation association is an independent body that evaluates these types of patient claims on behalf of the government.

Over the past year, we have heard from people with Ozempic vision loss claims who are seeking compensation payments. In the US, those claims would be filed as drug injury lawsuits in the court system.  When successful, the resulting legal compensation payments would be made by the responsible drug company, Novo Nordisk.

Among the liability allegations that would be asserted in the lawsuits for those US Ozempic vision loss claims is Novo Nordisk’s failure to warn that semaglutide has been linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in several medical studies. The current Ozempic drug label in the US does not have any warnings about NAION.

We are investigating Ozempic vision loss claims for patients who have been diagnosed with NAION, as well as similar cases with the use of Wegovy or Rybelsus, which are two other semaglutide-containing drugs from Novo Nordisk.

Again, these drug injury lawsuits with vision loss claims involving Ozempic, Wegovy, and Rybelsus would be filed against Novo Nordisk for its failure to warn about the increased risk of NAION associated with semaglutide in its current US drug labels for those semaglutide-containing drugs.

If you are interested, you can submit an online Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form. Attorney Tom Lamb reviews each one of these submissions. He evaluates them as possible drug injury lawsuits seeking compensation payments for the person suffering from a loss of vision or blindness due to NAION. This case evaluation service is free and confidential, and without obligation.

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

It has been reported during the past couple of years that drugs with the active ingredient semaglutide, such as Ozempic, can increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION). However, a new study presented this week at the 2025 annual meeting of the American Academy of Ophthalmology set the Ozempic NAION rate higher than we had seen previously.

From an October 20, 2025, News Release from the American Academy of Ophthalmology, “Do GLP-1 Drugs like Ozempic Cause or Prevent Vision Loss?“:

Researchers in an international collaboration across the University of Ottawa Eye Institute, University of Toronto, McMaster University, and Doheny Eye Institute UCLA conducted one of the largest global studies on the topic to date. Using data from the World Health Organization’s global database of drug safety reports, the authors analyzed data on 117,173 patients with diabetes taking semaglutide [Ozempic, as well as Rybelsus and Wegovy](GLP-1 drugs), empagliflozin, exenatide, tirzepatide, or insulin.

Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin. The analysis found no significant association between tirzepatide (the active ingredient in other GLP-1 medications including Mounjaro and Zepbound) and NAION or diabetic retinopathy. [Emphasis added]

The American Academy of Ophthalmology (AAO) is the world’s largest association of eye physicians and surgeons.  So it makes this “Ozempic NAION rate higher” announcement significant.

The earlier Ozempic NAION rates, which were significantly lower, had already resulted in drug injury lawsuits being filed by patients against the responsible pharmaceutical company, Novo Nordisk.

Here is an April 2025 Drug Injury Watch article that you can read to learn more about lawsuits involving NAION, titled “Ozempic Vision Loss Lawsuits Have Been Filed by Patients Against Novo Nordisk“. That article lists some of the legal liability allegations regarding Novo Nordisk’s actions and failures. It also points out that the current Ozempic drug label does not warn about NAION as a possible eye side effect that can cause vision loss or blindness.

One wonders whether a medical study with the Ozempic NAION rate higher, as announced by this October 2025 AAO News Release, might increase the number of Ozempic vision loss lawsuits.

If you are interested in a possible Ozempic lawsuit seeking legal compensation for your NAION eye side effect, you can submit an Online Case Evaluation Form. It is free, confidential, and there is no obligation. We will reply to you no later than the next business day.

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation